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EXECUTIVE SUMMARY
Native vertebral osteomyelitis (NVO) in adults is often
the result of hematogenous seeding of the adjacent disc
space from a distant focus, as the disc is avascular [1, 2].
The diagnosis of NVO can often be delayed several
months and may initially be misdiagnosed and mis-
managed as a degenerative process [3, 4]. NVO is typi-
cally diagnosed in the setting of recalcitrant back pain
unresponsive to conservative measures and elevated in-
ﬂammatory markers with or without fever. Plain
radiographs of the spine are not sensitive for the early
diagnosis of NVO. Magnetic resonance imaging (MRI)
of the spine is often required to establish the diagnosis.
Except in septic patients or patients with neurologic
compromise, empiric antimicrobial therapy should be
withheld, when possible, until a microbiologic diagno-
sis is conﬁrmed. An image-guided or intraoperative as-
piration or biopsy of a disc space or vertebral endplate
sample submitted for microbiologic and pathologic
examination often establishes the microbiologic or
pathologic diagnosis of NVO [5]. NVO is commonly
monomicrobial and most frequently due to Staphylo-
coccus aureus [6–8]. The concomitant presence of
S. aureus bloodstream infection within the preceding
3 months and compatible spine MRI changes preclude
the need for a disc space aspiration in most patients
[1, 9, 10]. Deﬁnitive therapy should be based on the re-
sults of culture and in vitro susceptibility testing. The
majority of patients are cured with a 6-week course of
antimicrobial therapy, but some patients may need
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surgical debridement and/or spinal stabilization during or after
a course of antimicrobial therapy [7, 11–13]. Indications for sur-
gery may include the development of neurologic deﬁcits or
symptoms of spinal cord compression and evidence of progres-
sion or recurrence despite proper antimicrobial therapy [6].
Most patients can be followed symptomatically and by monitor-
ing laboratory parameters such as C-reactive protein (CRP) and
erythrocyte sedimentation rate (ESR) [14]. Repeat imaging
studies should be reserved for patients failing to show clinical
and or laboratory improvement [15, 16].
Summarized below are the Infectious Diseases Society of
America (IDSA) recommendations pertaining to the diagnosis
and management of patients with NVO. The expert panel fol-
lowed a process used in the development of other IDSA guide-
lines, which included a systematic weighting of the strength of
recommendation and quality of evidence using the GRADE
(Grading of Recommendations Assessment, Development and
Evaluation) system [17–20] (Table 1). A detailed description
of the methods, background, and evidence summaries that sup-
port each of the recommendations can be found online in the
full text of the guidelines.
RECOMMENDATIONS FOR CLINICAL
DIAGNOSTICS
I. When Should the Diagnosis of NVO Be Considered?
Recommendations
1. Clinicians should suspect the diagnosis of NVO in patients
with new or worsening back or neck pain and fever (strong,
low).
2. Clinicians should suspect the diagnosis of NVO in patients
with new or worsening back or neck pain and elevated ESR
or CRP (strong, low).
3. Clinicians should suspect the diagnosis of NVO in patients
with new or worsening back or neck pain and bloodstream
infection or infective endocarditis (strong, low).
4. Clinicians may consider the diagnosis of NVO in patients
who present with fever and new neurologic symptoms with
or without back pain (weak, low).
5. Clinicians may consider the diagnosis of NVO in patients
who present with new localized neck or back pain, following
a recent episode of Staphylococcus aureus bloodstream infec-
tion (weak, low).
II. What Is the Appropriate Diagnostic Evaluation of Patients With
Suspected NVO?
Recommendations
6. We recommend performing a pertinent medical and motor/
sensory neurologic examination in patients with suspected
NVO (strong, low).
7. We recommend obtaining bacterial (aerobic and anaerobic)
blood cultures (2 sets) and baseline ESR and CRP in all pa-
tients with suspected NVO (strong, low).
8. We recommend a spine MRI in patients with suspected
NVO (strong, low).
9. We suggest a combination spine gallium/Tc99 bone scan, or
computed tomography scan or a positron emission tomogra-
phy scan in patients with suspected NVO when MRI cannot
be obtained (eg, implantable cardiac devices, cochlear implants,
claustrophobia, or unavailability) (weak, low).
10. We recommend obtaining blood cultures and serologic
tests for Brucella species in patients with subacute NVO re-
siding in endemic areas for brucellosis (strong, low).
11. We suggest obtaining fungal blood cultures in patients with
suspected NVO and at risk for fungal infection (epidemio-
logic risk or host risk factors) (weak, low).
12. We suggest performing a puriﬁed protein derivative (PPD)
test or obtaining an interferon-γ release assay in patients with
subacute NVO and at risk for Mycobacterium tuberculosis
NVO (ie, originating or residing in endemic regions or hav-
ing risk factors) (weak, low).
13. In patients with suspected NVO, evaluation by an infec-
tious disease specialist and a spine surgeon may be consid-
ered (weak, low).
III. When Should an Image-Guided Aspiration Biopsy or
Additional Workup Be Performed in Patients With NVO?
Recommendations
14. We recommend an image-guided aspiration biopsy in pa-
tients with suspected NVO (based on clinical, laboratory, and
imaging studies) when a microbiologic diagnosis for a known
associated organism (S. aureus, Staphylococcus lugdunensis,
and Brucella species) has not been established by blood cul-
tures or serologic tests (strong, low).
15. We advise against performing an image-guided aspiration bi-
opsy in patients with S. aureus, S. lugdunensis, or Brucella spe-
cies bloodstream infection suspected of having NVO based on
clinical, laboratory, and imaging studies (strong, low).
16. We advise against performing an image-guided aspiration
biopsy in patients with suspected subacute NVO (high en-
demic setting) and strongly positive Brucella serology
(strong, low).
IV. How Long Should Antimicrobial Therapy Be Withheld Prior to
an Image-Guided Diagnostic Aspiration Biopsy in Patients With
Suspected NVO?
Recommendations
17. In patients with neurologic compromise with or without
impending sepsis or hemodynamic instability, we recom-
mend immediate surgical intervention and initiation of em-
piric antimicrobial therapy (strong, low).
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V. When Is It Appropriate to Send Fungal, Mycobacterial, or
Brucellar Cultures or Other Specialized Testing Following an
Image-Guided Aspiration Biopsy in Patients With Suspected NVO?
Recommendations
18. We suggest the addition of fungal, mycobacterial, or bru-
cellar cultures on image-guided biopsy and aspiration speci-
mens in patients with suspected NVO if epidemiologic, host
risk factors, or characteristic radiologic clues are present
(weak, low).
19. We suggest the addition of fungal and mycobacterial cul-
tures and bacterial nucleic acid ampliﬁcation testing to ap-
propriately stored specimens if aerobic and anaerobic
bacterial cultures reveal no growth in patients with suspected
NVO (weak, low).
Table 1. Strength of Recommendations and Quality of the Evidence
Strength of
Recommendation and
Quality of Evidence
Clarity of Balance Between
Desirable and Undesirable
Effects
Methodological Quality of
Supporting Evidence (Examples) Implications
Strong recommendation,
high-quality evidence
Desirable effects clearly
outweigh undesirable
effects, or vice versa
Consistent evidence from well-
performed
RCTs or exceptionally strong
evidence from unbiased
observational studies
Recommendation can apply to most
patients in most circumstances.
Further research is unlikely to change
our confidence in the estimate of
effect.
Strong recommendation,
moderate-quality
evidence
Desirable effects clearly
outweigh undesirable
effects, or vice versa
Evidence from RCTs with important
limitations (inconsistent results,
methodological flaws, indirect, or
imprecise) or exceptionally strong
evidence from unbiased
observational studies
Recommendation can apply to most
patients in most circumstances.
Further research (if performed) is
likely to have an important impact on
our confidence in the estimate of
effect and may change the estimate.
Strong recommendation,
low-quality quality
evidence
Desirable effects clearly
outweigh undesirable
effects, or vice versa
Evidence for at least 1 critical
outcome from observational
studies, RCTs with serious flaws
or indirect evidence
Recommendation may change when
higher-quality evidence becomes
available. Further research (if
performed) is likely to have an
important impact on our confidence
in the estimate of effect and is likely
to change the estimate.
Strong recommendation,
very-low-quality evidence
(very rarely applicable)
Desirable effects clearly
outweigh undesirable
effects, or vice versa
Evidence for at least 1 critical
outcome from unsystematic
clinical observations or very
indirect evidence
Recommendation may change when
higher-quality evidence becomes
available; any estimate of effect for at
least 1 critical outcome is very
uncertain.
Weak recommendation,
high-quality evidence
Desirable effects closely
balanced with undesirable
effects
Consistent evidence from well-
performed
RCTs or exceptionally strong
evidence from unbiased
observational studies
The best action may differ depending
on circumstances or patients or
societal values. Further research is
unlikely to change our confidence in
the estimate of effect.
Weak recommendation,
moderate-quality
evidence
Desirable effects closely
balanced with undesirable
effects
Evidence from RCTs with important
limitations (inconsistent results,
methodological flaws, indirect, or
imprecise) or exceptionally strong
evidence from unbiased
observational studies
Alternative approaches likely to be
better for some patients under some
circumstances. Further research (if
performed) is likely to have an
important impact on our confidence
in the estimate of effect and may
change the estimate.
Weak recommendation,
low-quality evidence
Uncertainty in the estimates of
desirable effects, harms, and
burden; desirable effects,
harms, and burden may be
closely balanced
Evidence for at least 1 critical
outcome from observational
studies or from RCTs with serious
flaws or indirect evidence
Other alternatives may be equally
reasonable. Further research is very
likely to have an important impact on
our confidence in the estimate of
effect and is likely to change the
estimate.
Weak recommendation,
very low-quality evidence
Major uncertainty in the
estimates of desirable
effects, harms, and burden;
desirable effects may or may
not be balanced with
undesirable effects
Evidence for at least 1 critical
outcome from unsystematic
clinical observations or very
indirect evidence
Other alternatives may be equally
reasonable. Any estimate of effect,
for at least 1 critical outcome, is very
uncertain.
Abbreviation: RCT, randomized controlled trial.
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VI. When Is It Appropriate to Send the Specimens for Pathologic
Examination Following an Image-Guided Aspiration Biopsy in
Patients With Suspected NVO?
Recommendation
20. If adequate tissue can be safely obtained, pathologic spec-
imens should be sent from all patients to help conﬁrm a di-
agnosis of NVO and guide further diagnostic testing,
especially in the setting of negative cultures (strong, low).
VII. What Is the Preferred Next Step in PatientsWith Nondiagnostic
Image-Guided Aspiration Biopsy and Suspected NVO?
Recommendations
21. In the absence of concomitant bloodstream infection, we
recommend obtaining a second aspiration biopsy in patients
with suspected NVO in whom the original image-guided
aspiration biopsy specimen grew a skin contaminant (coag-
ulase-negative staphylococci [except S. lugdunensis], Propio-
nibacterium species, or diphtheroids) (strong, low).
22. In patients with a nondiagnostic ﬁrst image-guided aspira-
tion biopsy and suspected NVO, further testing should be
done to exclude difﬁcult-to-grow organisms (eg, anaerobes,
fungi, Brucella species, or mycobacteria) (strong, low).
23. In patients with suspected NVO and a nondiagnostic image-
guided aspiration biopsy and laboratory workup, we suggest
either repeating a second image-guided aspiration biopsy, per-
forming percutaneous endoscopic discectomy and drainage
(PEDD),orproceedingwithanopenexcisionalbiopsy(weak, low).
RECOMMENDATIONS FOR CLINICAL THERAPY
VIII. When Should Empiric Antimicrobial Therapy Be Started in
Patients With NVO?
Recommendations
24. In patients with normal and stable neurologic examination
and stable hemodynamics, we suggest holding empiric anti-
microbial therapy until a microbiologic diagnosis is estab-
lished (weak, low).
25. In patients with hemodynamic instability, sepsis, septic
shock, or severe or progressive neurologic symptoms, we sug-
gest the initiation of empiric antimicrobial therapy in con-
junction with an attempt at establishing a microbiologic
diagnosis (weak, low).
IX. What Is the Optimal Duration of Antimicrobial Therapy in
Patients With NVO?
Recommendations
26. We recommend a total duration of 6 weeks of parenteral
or highly bioavailable oral antimicrobial therapy for most
patients with bacterial NVO (strong, low).
27. We recommend a total duration of 3 months of antimicro-
bial therapy for most patients with NVO due to Brucella
species (strong, moderate).
X. What Are the Indications for a Surgical Intervention in Patients
With NVO?
Recommendations
28. We recommend surgical intervention in patients with pro-
gressive neurologic deﬁcits, progressive deformity, and spinal
instability with or without pain despite adequate antimicro-
bial therapy (strong, low).
29. We suggest surgical debridement with or without stabiliza-
tion in patients with persistent or recurrent bloodstream in-
fection (without alternative source) or worsening pain
despite appropriate medical therapy (weak, low).
30. We advise against surgical debridement and/or stabilization
in patients who have worsening bony imaging ﬁndings at 4–6
weeks in the setting of improvement in clinical symptoms,
physical examination, and inﬂammatory markers (weak, low).
RECOMMENDATIONS FORCLINICAL FOLLOW-UP
XI. How Should Failure of Therapy Be Deﬁned in Treated Patients
With NVO?
Recommendation
31. We suggest that persistent pain, residual neurologic deﬁ-
cits, elevated markers of systemic inﬂammation, or radio-
graphic ﬁndings alone do not necessarily signify treatment
failure in treated NVO patients (weak, low).
XII. What Is the Role of Systemic Inﬂammatory Markers and MRI
in the Follow-up of Treated Patients With NVO?
Recommendations
32. We suggest monitoring systemic inﬂammatory markers
(ESR and or CRP) in patients with NVO after approximately
4 weeks of antimicrobial therapy, in conjunction with a clin-
ical assessment (weak, low).
33. We recommend against routinely ordering follow-up MRI
in patients with NVO in whom a favorable clinical and lab-
oratory response to antimicrobial therapy was observed
(strong, low).
34. We suggest performing a follow-up MRI to assess evolu-
tionary changes of the epidural and paraspinal soft tissues
in patients with NVO who are judged to have a poor clinical
response to therapy (weak, low).
XIII. How Do You Approach a Patient With NVO and Suspected
Treatment Failure?
Recommendations
35. In patients with NVO and suspected treatment failure, we
suggest obtaining markers of systemic inﬂammation (ESR
and CRP). Unchanged or increasing values after 4 weeks of
treatment should increase suspicion for treatment failure
(weak, low).
36. We recommend obtaining a follow-up MRI with emphasis
on evolutionary changes in the paraspinal and epidural soft
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tissue ﬁndings in patients with NVO and suspected treat-
ment failure (strong, low).
37. In patients with NVO and clinical and radiographic
evidence of treatment failure, we suggest obtaining additional
tissue samples for microbiologic (bacteria, fungal, and myco-
bacterial) and histopathologic examination, either by image-
guided aspiration biopsy or through surgical sampling (weak,
very low).
38. In patients with NVO and clinical and radiographic evi-
dence of treatment failure, we suggest consultation with a
spine surgeon and an infectious disease physician (weak,
very low).
INTRODUCTION
The incidence of NVO varies by country, age of the population
studied, and whether endemic infections are included. In one
study from France, the overall incidence of NVO was 2.4 per
100 000. The incidence increased with age to reach 6.5 per
100 000 in patients 50–70 years of age [21]. Although rare,
NVO is the most common form of hematogenous osteomyelitis
in patients aged >50 years and represents 3%–5% of all cases of
osteomyelitis [8]. An increase in the incidence of NVO has been
attributed to an increase in susceptible patients such as intrave-
nous drug users, individuals undergoing hemodialysis, and
immunocompromised hosts.
The diagnosis of NVO may be difﬁcult and requires many
different modalities including serologic, radiographic, and mi-
crobiologic diagnostic tests. For the purpose of these guidelines,
the term “image-guided aspiration biopsy” epitomizes a needle
aspiration, typically from disc space, performed either under
computed tomographic (CT) or ﬂuoroscopic guidance. The as-
piration biopsy typically incorporates 2 specimens: aspiration
ﬂuid and a tissue sample. The management of NVO necessitates
a prolonged course of intravenous and or oral antimicrobial
therapy as well as surgical debridement in almost 50% of pa-
tients [6]. Many questions pertaining to the optimal diagnostic
strategies and management of patients with NVO remain unan-
swered. The primary focus of these guidelines will be to provide
evidence-based guidelines, and, if that is not possible, consensus
statements that address current controversies in the diagnosis
and management of patients with NVO. An exhaustive review
of the pathophysiology of NVO is not within the scope of these
guidelines. Interested readers are encouraged to review selected
references [1, 22, 23]. For the purpose of the guidelines, the fol-
lowing terms will be used: bacterial NVO, brucellar NVO, fun-
gal NVO, or mycobacterial NVO, with bacterial NVO
denominating infections due to common bacterial infections
(eg, staphylococci, aerobic gram-negatives, streptococci, and
anaerobes). The other terms are self-explanatory. In many
instances, the panel has made recommendations based on ex-
pert opinion only, realizing that the amount of data to support
a speciﬁc recommendation is limited. The panel acknowledges
that there are diverse practice patterns that seem to be equally
effective in the management of NVO. However, an essential ad-
vantage of this speciﬁc therapeutic approach is the strong col-
laboration between all involved medical and surgical specialists
(eg, orthopedic surgeons, radiologists, neurosurgeons, infec-
tious disease specialists, pain specialists). It is anticipated that
adoption of these guidelines may help reduce morbidity, mor-
tality, and the costs associated with the management of NVO.
The panel acknowledges that not all medical institutions will have
the adequate resources to implement all of the recommendations
in these guidelines. Proper referral may be needed. The panel
elected not to address patients with spinal implant–associated in-
fections, patients with postprocedure infections, and patients
with epidural abscess without associated NVO. The management
of these entities may differ from the management of patients with
NVO. These topics can be addressed in future guidelines. The
panel addressed the following 13 clinical questions:
(I) When should the diagnosis of NVO be considered?
(II) What is the appropriate diagnostic evaluation of patients
with suspected NVO?
(III) When should an image-guided aspiration biopsy or ad-
ditional workup be performed in patients with NVO?
(IV) How long should antimicrobial therapy be withheld
prior to an image-guided diagnostic aspiration biopsy in pa-
tients with suspected NVO?
(V) When is it appropriate to send fungal, mycobacterial, or
brucellar cultures or other specialized testing following an
image-guided aspiration biopsy in patients with suspected
NVO?
(VI) When is it appropriate to send the specimens for path-
ologic examination following an image-guided aspiration biop-
sy in patients with suspected NVO?
(VII) What is the preferred next step in patients with non-
diagnostic image-guided aspiration biopsy and suspected NVO?
(VIII) When should empiric antimicrobial therapy be start-
ed in patients with NVO?
(IX) What is the optimal duration of antimicrobial therapy
in patients with NVO?
(X) What are the indications for a surgical intervention in
patients with NVO?
(XI) How should failure of therapy be deﬁned in treated pa-
tients with NVO?
(XII) What is the role of systemic inﬂammatory markers and
MRI in the follow-up of treated patients with NVO?
(XIII) How do you approach a patient with NVO and sus-
pected treatment failure?
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PRACTICE GUIDELINES
Practice guidelines are systematically developed statements to
assist practitioners and patients in making decisions about ap-
propriate healthcare delivery for speciﬁc clinical circumstances
[24]. Attributes of high-quality guidelines include validity, reli-
ability, reproducibility, clinical applicability, clinical ﬂexibility,
clarity, multidisciplinary process, review of evidence, and doc-
umentation [24].
METHODOLOGY
Panel Composition
We convened a panel of 11 experts, including specialists in in-
fectious diseases, spine orthopedic surgery, and neuroradiology.
The panel included physicians afﬁliated with an academic insti-
tution, and physicians who are mainly clinicians. One is a spine
orthopedic surgeon and 1 is a neuroradiologist. Among the 11
panel members, 9 are from the United States, 1 is from Europe,
and 1 is from the Middle East.
Literature Review and Analysis
In accordance with the IDSA format, the panel identiﬁed 13
clinical questions to address and assigned 3 different groups
in charge of drafting responses to the questions identiﬁed, di-
vided into the Diagnosis, Management, and Follow-up sec-
tions of the guidelines. Panel members thoroughly reviewed
the literature pertinent to each of the questions using
PubMed/Medline, Cochrane Library, Elton B. Stephens Com-
pany, CINAHL (Cumulative Index to Nursing and Allied
Health Literature), Google Scholar, the National Guidelines
Clearinghouse, ClinicalTrials.gov, references in published arti-
cles, pertinent websites, textbooks, and abstracts of original re-
search and review articles in any language on NVO.
The search looked at publications from 1970 to December
2014 to ﬁnd articles that assessed NVO using the following key-
words: vertebral osteomyelitis, pyogenic, infectious, discitis,
spondylodiscitis, spinal infection, epidural abscess, diagnostic,
therapy, aspiration, antimicrobial therapy, MRI, treatment, em-
piric antimicrobial therapy, and surgical intervention.
Process Overview
In creating the guidelines, the panel followed the newly created
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) system recommended by IDSA. This
included systematically weighing the quality of the available
evidence and grading our recommendations. To evaluate
evidence, the panel followed a process consistent with other
IDSA guidelines, including a systematic weighing of the
quality of the evidence and the grade of recommendation.
High-quality evidence does not necessarily lead to strong
recommendations; conversely, strong recommendations can
arise from low-quality evidence if one can be conﬁdent that
the desired beneﬁts clearly outweigh the undesirable conse-
quences. The main advantages of the GRADE approaches
are the detailed and explicit criteria for grading the quality
of evidence and the transparent process for making recom-
mendations [17–20] (Table 1). This system requires that the
assigned strength of a recommendation be either “strong” or
“weak.” The main criterion for assigning a “strong” recom-
mendation is that the potential beneﬁts clearly outweigh the
potential risks. The panel chair reviewed all the recommenda-
tion grading and then worked with the panel to achieve con-
sensus via regular teleconference and email communications.
Consensus Development Based on Evidence
The panel members met in person twice, during the 2010 and
2012 IDSA annual meetings, and participated in 9 teleconfer-
ences. The chair presented a preliminary version of the guide-
lines in 2012 and sought feedback via email from the panel.
All panel members participated in the preparation of the clinical
questions and writing for the draft guidelines, which were then
collated, revised and disseminated for review to the entire panel.
The guidelines were reviewed and endorsed by the European
Society for Microbiology and Infectious Diseases, Musculoskel-
etal Infection Society, American Society of Spine Radiology, and
Radiologic Spine Society. We also sought and received extensive
feedback from several external reviewers, and the guideline
manuscript was reviewed and approved by the IDSA Standards
and Practice Guidelines Committee (SPGC) and by the IDSA
Board of Directors (Steven Schmidt recused himself from
Board approval as he was a member of the guideline panel).
Guidelines and Conﬂicts of Interest
All members of the expert panel complied with the IDSA policy
regarding conﬂicts of interest, which requires disclosure of any
ﬁnancial or other interests that might be construed as constitut-
ing an actual, potential, or apparent conﬂict. Members of the
expert panel were provided a conﬂicts of interest disclosure
statement from IDSA and were asked to identify ties to compa-
nies developing products that might be affected by promulga-
tion of the guidelines. The statement requested information
regarding employment, consultancies, stock ownership, hono-
raria, research funding, expert testimony, and membership on
company advisory committees. The panel was instructed to
make decisions on a case-by-case basis as to whether an individ-
ual’s role should be limited as a result of a conﬂict, but no lim-
iting conﬂicts were identiﬁed.
Revision Dates
At annual intervals, the panel chair, the liaison advisor, and the
chair of the SPGC will determine the need for revisions of the
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updated guidelines based on an examination of current litera-
ture. If necessary, the entire panel will reconvene to discuss
potential changes. When appropriate, the panel will recom-
mend full revision of the guidelines to the IDSA SPGC and
the Board for review and approval.
RECOMMENDATIONS FOR CLINICAL
DIAGNOSTICS
I. When Should the Diagnosis of NVO Be Considered?
Recommendations
1. Clinicians should suspect the diagnosis of NVO in patients
with new or worsening back or neck pain and fever (strong,
low).
2. Clinicians should suspect the diagnosis of NVO in patients
with new or worsening back or neck pain and elevated ESR
or CRP (strong, low).
3. Clinicians should suspect the diagnosis of NVO in patients
with new or worsening back or neck pain and bloodstream
infection or infective endocarditis (strong, low).
4. Clinicians may consider the diagnosis of NVO in patients
who present with fever and new neurologic symptoms with
or without back pain (weak, low).
5. Clinicians may consider the diagnosis of NVO in patients
who present with new localized neck or back pain, following
a recent episode of Staphylococcus aureus bloodstream infec-
tion (weak, low).
Evidence Summary
NVO is a serious condition and if the diagnosis is delayed, it
may lead to permanent spinal cord injury or septicemia. Be-
cause idiopathic back or neck pain are extremely common
symptoms, the diagnosis of rare, albeit serious conditions
such as infection or malignancy of the spine is often delayed.
In one study, the average time to diagnosis was 2–4 months
[25]. In another study, 34% of 101 patients with NVO were ini-
tially misdiagnosed [26]. The diagnosis can also be delayed in
paraplegic patients [27]. Patients who are elderly, immunocom-
promised, or active intravenous drug abusers (IVDAs), have
indwelling central catheters, or have undergone recent instru-
mentation are most at risk for bacterial NVO [28, 29].Mycobac-
terium tuberculosis and Brucella species should be considered in
areas of high endemicity [30]. Mycobacterium avium complex
NVO should be considered in human immunodeﬁciency
virus-infected patients presenting with back pain in the setting
of immune reconstitution following initiation of antiretroviral
therapy. The diagnosis of NVO is straightforward when patients
present with focal acute back pain and fever. In this circum-
stance, imaging studies can lead to an accurate and deﬁnitive
diagnosis. However, fever is only present in up to 45% of pa-
tients with bacterial NVO. Fever is rarely present in patients
with mycobacterial, brucellar, or fungal NVO and may be
masked in patients taking analgesics with antipyretic effects
[31–35]. In patients with insidious chronic back pain or in pa-
tients with paraplegia, the diagnosis can be overlooked due to
other, more common causes of back or neck pain. The pain is
typically localized to the infected disc space area and is exacer-
bated by physical activity or percussion to the affected area. Pain
may radiate to the abdomen, hip, leg, scrotum, groin, or perine-
um [36]. Paravertebral muscle tenderness and spasm, and lim-
itation of spine movement, are the predominant physical
examination ﬁndings. In a series of 253 patients with bacterial
NVO, 43% had epidural or paravertebral extension [6]. Spinal
cord or nerve root compression and meningitis may occur.
Neurologic signs and symptoms are more commonly encoun-
tered in patients with cervical or thoracic involvement.
An elevated ESR or CRP result in patients with back pain,
though not speciﬁc, has a sensitivity that can range from 94%
to 100% [37, 38]. These inﬂammatory markers are often used to
rule out the presence of an infection or a malignancy in patients
with protracted back pain. Up to 40% of patients with NVO have
a normal white blood cell (WBC) count [37]. Screening for mul-
tiple myeloma with an serum protein electrophoresis may be war-
ranted, if the original workup including an image-guided biopsy
remains inconclusive.
A history of back pain or radicular symptoms should be elic-
ited in patients with a history of or concomitant Staphylococcus
aureus bloodstream infection in the previous year [1, 9, 10].
A careful examination and percussion of the spine is warranted
[37]. Patients with concomitant back pain and S. aureus blood-
stream infection should be further investigated with an imaging
study to rule out the presence of NVO or paraspinal abscess.
II. What Is the Appropriate Diagnostic Evaluation of Patients With
Suspected NVO?
Recommendations
6. We recommend performing a pertinent medical and motor/
sensory neurologic examination in patients with suspected
NVO (strong, low).
7. We recommend obtaining bacterial (aerobic and anaerobic)
blood cultures (2 sets) and baseline ESR and CRP in all pa-
tients with suspected NVO (strong, low).
8. We recommend a spine MRI in patients with suspected
NVO (strong, low).
9. We suggest a combination spine gallium /Tc99 bone scan, or
computed tomography scan or a positron emission tomogra-
phy scan in patients with suspected NVO when MRI cannot
be obtained (eg, implantable cardiac devices, cochlear im-
plants, claustrophobia, or unavailability) (weak, low).
10. We recommend obtaining blood cultures and serologic
tests for Brucella species in patients with subacute cases of
NVO residing in endemic areas for brucellosis (strong, low).
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11. We suggest obtaining fungal blood cultures in patients with
suspected NVO and at risk for fungal infection (epidemio-
logic risk or host risk factors) (weak, low).
12. We suggest performing a PPD test or obtaining an interfer-
on-γ release assay in patients with subacute NVO and at risk
for Mycobacterium tuberculosis NVO (ie, originating or re-
siding in endemic regions or having risk factors) (weak, low).
13. In patients with suspected NVO, evaluation by an infec-
tious disease specialist and a spine surgeon may be consid-
ered (weak, low).
Evidence Summary
Medical and neurologic history and examinations should
be performed on all patients with suspected NVO, including
looking for signs of potential entry sources of hematogenous
seeding. Pertinent history should focus on prior use of antimi-
crobials and prior surgical procedures, as well as history of uri-
nary tract infection, bloodstream infection, skin or soft tissue
infection, and intravenous drug use. An appropriate neurologic
and medical examination should include an assessment of a
motor and sensory function, including assessment for intestinal
and urinary incontinence as well as signs and symptoms of in-
fective endocarditis. It takes 3–6 weeks after the onset of symp-
toms for bone destruction to be evident on plain
roentgenography. MRI, when feasible, should be the ﬁrst diag-
nostic imaging of choice in patients with suspected NVO [39–
41].MRI of the spine has a sensitivity of 97%, speciﬁcity of 93%,
and an accuracy of 94% in diagnosing NVO [41, 42].The inabil-
ity to distinguish the margins between the disc space and adja-
cent vertebral marrow on T1-weighted images associated with
increased signal intensity from the disc and the adjacent in-
volved marrow on T2-weighted images is the hallmark of bac-
terial NVO. In tuberculous or brucellar NVO, T1-weighted
sequences appear to be more sensitive than T2-weighted se-
quences in demonstrating the inﬂammatory processes in the
vertebral bodies [43]. Extension of the infectious process to
the paravertebral space causing an epidural abscess or a para-
vertebral abscess is best seen on the gadolinium with diethyle-
netriaminepentacetate (Gd-DTPA)–enhanced MRI. Gd-DTPA
enhancement may be the ﬁrst sign of an acute inﬂammatory
process and is used to enhance speciﬁcity [39]. MRI can also
differentiate NVO frommore common degenerative, traumatic,
or neoplastic diseases. A repeat examination may be warranted
within 1–3 weeks if the initial imaging study fails to show typ-
ical features of NVO [44].
In patients with implantable devices or severe claustrophobia,
in whom MRI cannot be performed, a combination spine galli-
um/Tc99 bone scan can be performed. Gallium 67 (Ga67) is a
group III b transition metal that is analogous to iron. It binds to
lactoferrin produced by neutrophils, and siderophores pro-
duced by microorganisms. Gallium spine scan is typically
combined with a bone scan and has a speciﬁcity of >90%. Its
sensitivity of 91% makes it a valuable test to rule out NVO in
patients with a questionable diagnosis [45, 46]. Indium-tagged
WBC scanning lacks sensitivity in the diagnosis of NVO and
should not be primarily used in establishing the diagnosis of
NVO [47].
CT scanning is useful to assess the degree of bony and soft
tissue involvement and is a very useful test to guide the percu-
taneous needle aspiration biopsy. Adjacent bone edema and
narrowing of the disk space are among the earliest and most
consistent ﬁndings but may be nonspeciﬁc. Positron emission
tomographic (PET) scanning is highly sensitive for detecting
chronic osteomyelitis. A negative PET scan excludes the diagno-
sis of osteomyelitis, including NVO, as the sensitivity of the test
is expected to be very high in view of the high concentration of
red marrow in the axial skeleton [48]. Selected third-party pay-
ers may limit reimbursement of PET scanning to patients with
malignancy. Prior authorization may be warranted in these
circumstances.
A minimum of 2 bacterial blood cultures (aerobic and anaer-
obic) sets should be routinely sent for all patients with suspected
NVO [49, 50]. When brucella is suspected, such as in patients
with high epidemiologic risk, blood cultures should be incubat-
ed for up to 2 weeks and Brucella serologic testing should be
performed. Outside the United States, the Coombs test is com-
monly used for the diagnosis of brucellar NVO [51]; in one
study, a titer of ≥1:160 was found in all patients with brucellar
NVO [40]. Enzyme-linked immunosorbent assay (ELISA) has
proven to be superior in complicated cases of brucellosis and
might be of value in patients with brucellar NVO [51].
Fungal vertebral osteomyelitis is rare and can occur in
patients with certain epidemiologic risks (blastomycosis, coc-
cidioidomycosis, or histoplasmosis) or certain host risk factors
such as immunocompromised hosts (Aspergillus species),
IVDA, indwelling intravenous catheters (Candida species,
Aspergillus species) [52–61]. Fungal serologies, antigen detec-
tion assays, and fungal blood cultures may aid in the diagnosis
of patients at risk [62–67]. Routine blood cultures may also
detect candidemia.
In patients with NVO with suspected tuberculous infection
who reside in or have a history of residence in endemic areas,
a PPD test or an interferon-γ release assay may be useful. How-
ever, false-positive and false-negative results may be encoun-
tered with these tests. Hence, in a scenario of high clinical
suspicion, we recommend submission of aspiration specimens
from an image-guided aspiration biopsy for mycobacterial tis-
sue cultures regardless of the results of these tests. Radiographic
ﬁndings that should raise suspicion forMycobacterium tubercu-
losisNVO infection include (1) destruction of 2 or more contig-
uous vertebrae and their opposed endplates, (2) spread along
the anterior longitudinal ligament, (3) disc infection with or
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without a paraspinal mass or mixed soft tissue ﬂuid collection,
or, less commonly, (4) spondylitis without disc involvement
[68]. An interferon-γ release assay has been shown to have a
higher sensitivity than PPD, especially in patients with altered
immunity [69]. A recent study found a higher sensitivity and
speciﬁcity of enzyme-linked immunospot assay compared
with PPD in the diagnosis of tuberculous NVO (sensitivity,
82.8% vs 58.6% and speciﬁcity, 81.3% vs 59.4%, respectively)
[70].
III. When Should an Image-Guided Aspiration Biopsy or
Additional Workup Be Performed in Patients With NVO?
Recommendations
14. We recommend an image-guided aspiration biopsy in all
patients with suspected NVO (based on clinical, laboratory,
and imaging studies) when a microbiologic diagnosis for a
known associated organism (S. aureus, Staphylococcus lugdu-
nensis, and Brucella species) has not been established by
blood cultures or serologic tests (strong, low).
15.We advise against performing an image-guided aspiration bi-
opsy in patients with S. aureus, S. lugdunensis, or Brucella spe-
cies bloodstream infection suspected of having NVO based on
clinical, laboratory, and imaging studies (strong, low).
16.We advise against performing an image-guided aspiration bi-
opsy in patients with suspected subacute NVO (high endemic
setting) and strongly positive Brucella serology (strong, low).
Evidence Summary
Empiric antimicrobial treatment of NVO should be deferred
when possible until a diagnostic image-guided aspiration and/
or biopsy of the affected area is obtained. Empiric therapy
should not be deferred in life-threatening conditions such as
sepsis or impending spinal cord compression. Every effort
should be made to identify the offending pathogen prior to
initiation of antimicrobial therapy. Image-guided diagnostic
aspiration biopsy sampling should be the ﬁrst invasive diagnos-
tic step in patients suspected of having NVO. The aspiration
biopsy may lead to a microbiologic diagnosis and obviate the
need for open surgical intervention in 50%–60% of cases or
more [5, 71–73]. Pathologic examination of aspiration speci-
mens may help differentiate an infectious from a malignant
or degenerative process. The sensitivity of the image-guided
biopsy in evaluated studies varied between 30% and 74%
[5, 74, 75]. Reported complications of image-guided aspiration
biopsy sampling include aortic and vascular injuries, psoas
muscle puncture or nerve damage, hematoma formation, and
biopsy of incorrect level [76]. Although severe, these complica-
tions are exceedingly rare when this procedure is performed by
a trained operator.
Image-guided specimens should be processed for pathological
examination looking for the presence of acute or chronic
inﬂammation, granuloma formation, andmalignancy. In addition
to bacterial cultures, mycobacterial, brucellar, and fungal cultures
should be obtained in cases of subacute and chronic NVO [52].
The main microbiologic etiology of bacterial NVO is S. aureus
[9]. Blood cultures can be positive in up to 50% of cases of
S. aureus NVO. A positive blood culture for S. aureus obviates
the need for an image-guided aspiration specimen in patients
with clinical, laboratory, and radiologic ﬁndings suggestive of
NVO [1, 10, 77]. In a national study from Denmark of 8739 pa-
tients with S. aureus bloodstream infection, an incidence of 6% of
associated NVO was found in patients aged > 50 years in whom
no obvious entry source was identiﬁed [77].Staphylococcus lugdu-
nensis has been associated with deep-seated infections and can
often behave like S. aureus [78, 79]. A persistently positive blood
culture for this organism in NVO may obviate the need for an
image-guided biopsy. A sustained bloodstream infection with
other coagulase-negative staphylococci in patients with suspected
NVO receiving chronic hemodialysis or in patients with infected
intravascular devices may also obviate the need for image-guided
aspiration biopsy [80, 81]. The need for an image-guided aspira-
tion biopsy in patients with suspected NVO and concomitant
bloodstream infection with other microorganisms (ie, Candida
species, Enterobacteriaceae, streptococci, Pseudomonas species)
is left to the discretion of the treating physicians.
In endemic countries, Brucella is a very common cause of
NVO. In a recent study from Greece, 11 of 33 patients admitted
with spinal infections to a teaching hospital had brucellosis [40,
82]. A false-negative serologic test is unusual in patients with
brucellar NVO. In one study, all patients with brucellar NVO
had serum antibody titers of ≥1:160 [40]. For serum agglutina-
tion and Coombs titers, the cutoff point is≥1:160. In an endemic
setting, patients with suspected brucellar NVO with either posi-
tive blood cultures or serology may not require image-guided as-
piration biopsy to conﬁrm the diagnosis. In the United States, a
low-endemicity country, an ELISA screen is performed initially,
followed by a conﬁrmatory agglutination test [52]. In this set-
ting, a false-positive test for Brucella serology is more likely
and an image-guided aspiration biopsy may be warranted
[83]. Given the rarity of this infection in nonendemic areas,
an evaluation by a spine surgeon and an infectious disease spe-
cialist is advised in the course of management of patients with
brucellar NVO [52].
IV. How Long Should Antimicrobial Therapy Be Withheld Prior to
an Image-Guided Diagnostic Aspiration Biopsy in Patients With
Suspected NVO?
Recommendation
17. In patients with neurologic compromise with or without im-
pending sepsis or hemodynamic instability, we recommend
immediate surgical intervention and initiation of empiric
antimicrobial therapy (strong, low).
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Evidence Summary
Prior exposure to antimicrobial therapy has been associated
with a decrease in the microbiologic yield of the image-guided
biopsy in patients with NVO [72, 84–86]. In one study, this
association was not statistically signiﬁcant [87].Holding antimi-
crobial therapy for a limited period of time prior to an image-
guided aspiration biopsy to increase the sensitivity of culture
results has been advocated [72, 84–86]. Pending further studies,
the panel believes that holding antibiotics when feasible for 1–2
weeks is reasonable [88]. The optimal duration to hold anti-
microbials may also be dependent on the half-life of the antimi-
crobial used and its postantibiotic effect. In patients with
neurologic compromise, immediate surgical intervention and
use of antimicrobial therapy are often required [89]. Further-
more, the panel believes that clinicians should not withhold an-
timicrobial therapy prior to image-guided biopsy in patients
with impending sepsis or hemodynamic instability.
V. When Is It Appropriate to Send Fungal, Mycobacterial, or
Brucellar Cultures or Other Specialized Testing Following an
Image-Guided Aspiration Biopsy in Patients With Suspected
NVO?
Recommendations
18. We suggest the addition of fungal, mycobacterial, or bru-
cellar cultures on image-guided biopsy and aspiration speci-
mens in patients with suspected NVO if epidemiologic, host
risk factors, or characteristic radiologic clues are present
(weak, low).
19. We suggest the addition of fungal and mycobacterial cul-
tures, and bacterial nucleic acid ampliﬁcation testing to ap-
propriately stored specimens if aerobic and anaerobic
bacterial cultures reveal no growth in patients with suspected
NVO (weak, low).
Evidence Summary
The epidemiology of the causative agents for NVO varies across
the geographic locations. In the majority of the world, typical
bacterial agents such as S. aureus, streptococcal species, enteric
bacteria, and other gram-negative rods are the most common
pathogens identiﬁed in NVO [9]. However, in certain endemic
regions, M. tuberculosis and Brucella species are among the
common causative agents of NVO. Mete et al reported 100
cases of NVO in one center in Turkey between 2000 and
2007; 44% had typical bacterial pathogens, 24% had Brucella
species, and 32% had M. tuberculosis [90]. In another study,
Sakkas et al describe the epidemiology of NVO in a single center
in central Greece over the same time period (2000–2007). Bac-
terial NVO accounted for 58% of the cases, Brucella species for
34%, and M. tuberculosis for 9% [91]. Using a national hospital
database in France between 2002 and 2003, Grammatico et al
reported that typical bacterial pathogens accounted for 58%,
tuberculosis for 31%, and Brucella species for 0.7% of the
cases [21].
There is a signiﬁcantly higher incidence of human brucellosis
in Spain and other countries of the Mediterranean basin, Latin
America, the Middle East, parts of Africa, and Western Asia
[92]. In a large retrospective study in Spain between 1982 and
2005, 918 patients were identiﬁed with brucellar infection,
of which 10.4% had NVO [93]. For patients with suspected
NVO from highly endemic countries, we recommend that
Brucella species be considered in the differential diagnosis. In
addition to brucellar serology tests and appropriate blood cul-
tures, samples of image-guided aspiration biopsy should be cul-
tured for bacteria when blood cultures and serology tests fail to
conﬁrm the diagnosis. When brucellar NVO is suspected, the
physician is advised to alert the microbiology laboratory per-
sonnel to use extended incubation techniques and to mitigate
the risk of laboratory-acquired Brucella infection.
Similarly, tuberculous NVO is seen with a greater frequency
in parts of the world that have a higher incidence of disease. Tu-
berculosis is the most common cause of spinal infections world-
wide [94–96]. In countries with low tuberculosis incidence,
tuberculous NVO (Pott disease) is most commonly encountered
in patients coming from areas of higher endemicity. In devel-
oped countries with low tuberculosis incidence, tuberculous
NVO is seen in older patients (>40 years of age), whereas in
countries with higher incidence, Pott disease is more commonly
seen in children [94–96].
For patients with suspected NVO from regions of the world
that have a higher incidence of tuberculosis, we suggest that Pott
disease be considered in the differential diagnosis and that pa-
tients should be carefully evaluated for active tuberculosis at
other sites. Tissue specimens should be sent for mycobacterial
stain and culture. In addition, molecular tests can aid in the di-
agnosis. Polymerase chain reaction (PCR) was found in one
study to have high sensitivity, speciﬁcity, and accuracy (95%,
83%, and 92%, respectively) in detecting M. tuberculosis from
formaldehyde solution–ﬁxed, parafﬁn-embedded tissue sam-
ples from histologically proven tuberculous spondylitis [97]. A
comparative study of bacterial and mycobacterial NVO found
that tuberculosis more commonly involves 3 or more vertebral
bodies, compared with bacterial infections. Although this ﬁnd-
ing does not exclude bacterial NVO, the clinician should con-
sider screening for M. tuberculosis when radiographic pictures
are suggestive [98].MRI of patients with NVO due to M. tuber-
culosis typically have >1 level involvement, larger paravertebral
abscesses, heterogeneous magnetic resonance intensity of the
involved vertebral bodies, increased rim enhancement with
Gd-DTPA, and are more likely to have a thoracic level of
involvement compared with patients with bacterial NVO
[99, 100]. Although MRI ﬁndings of brucellar NVO tend to sig-
niﬁcantly overlap with the ﬁndings of bacterial NVO, patients
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with brucellar NVO tend to have multilevel involvement and
are less likely to have paravertebral collections [93]. Nontuber-
culous mycobacteria are rare causes of NVO but have been
described in immunocompromised patients including those
who have systemic lupus erythematous on receiving steroids,
AIDS, interferon receptor defects, carcinoma, and chronic
granulomatous disease (CGD) [101]. Intravesicular bacillus
Calmette-Guerin (BCG) therapy used to treat carcinoma in
situ of the bladder has also been associated with BCG NVO.
In patients with intractable back pain, a history of bladder
cancer treated with intravesical BCG instillation should be
elucidated [102].
Fungal NVO is rare and is most commonly seen in immuno-
compromised patients. Fungal pathogens account for 0.5%–
1.6% of the cases of NVO [95]. Risk factors for these pathogens
are signiﬁcant immunosuppression including steroid use, pres-
ence of a long-term indwelling venous catheter, IVDA, neutro-
penia, and CGD [95].
We suggest for patients with signiﬁcant impairment of their
immunity and clinical and radiographic evidence of NVO to
have biopsy material sent for bacterial, mycobacterial, and fun-
gal stains and cultures.
There are no studies to guide a clinician on managing pa-
tients with signiﬁcant clinical or radiographic evidence of
NVO and who have sterile blood cultures and an initial non-
diagnostic spinal aspiration biopsy result. Studies have shown
that microbiologic diagnosis is established in 50%–90% of pa-
tients who are aspirated off antibiotics [9, 103, 104]. In one
study, the yield was found to increase with open biopsy (93%)
compared with needle aspiration biopsy (48%) [103]. Despite
the lack of data, we suggest that if a repeat diagnostic aspiration
biopsy is performed, material should be sent for (1) Gram stain
and aerobic culture, (2) mycobacterial stain and culture (and
nucleic acid ampliﬁcation testing if available), (3) brucellar cul-
ture, (4) fungal stain and culture, and (5) pathology. Epidemi-
ologic considerations will need to be made when determining
what to test for if specimen is insufﬁcient for all studies.
Molecular diagnostic tools have improved the yield of micro-
biologic diagnosis via tissue biopsy in several studies [105–108].
These techniques are widely available and currently adopted in
routine practice in many centers in Europe. Broad-range PCR
might prove to be important in patients who have received
prior antimicrobial therapy [105]. Most of these studies used
nonstandardized but well-accepted 16S ribosomal RNA PCR
techniques. These studies have been especially useful in the di-
agnosis of brucellar and mycobacterial NVO [97, 106, 107].Mo-
lecular techniques have also been used with fungal infections
and have enhanced the sensitivity of conventional methods
used in diagnostic mycology. These techniques mainly rely on
PCR for the detection of fungal-speciﬁc nucleic acids in clinical
specimens [108].
VI. When Is It Appropriate to Send the Specimens for Pathologic
Examination Following an Image-Guided Aspiration Biopsy in
Patients With Suspected NVO?
Recommendation
20. If adequate tissue can be safely obtained, pathology speci-
mens should be sent from all patients to help conﬁrm a diag-
nosis of NVO and to help guide further diagnostic testing,
especially in the setting of negative cultures (strong, low).
Evidence Summary
The differential diagnosis of a patient with back pain and an
MRI abnormality includes NVO, neoplasm, acute disc hernia-
tion with disc space collapse, and osteoporosis-associated verte-
bral collapse (vertebral compression fracture). Most patients
with bacterial NVO will have inﬂammatory changes in the
disc space with associated end-plate changes of the 2 adjacent
vertebral bodies. Exceptions, however are seen, especially in
early tuberculous NVO where disease may be limited to the ver-
tebral body only and may be misread as a likely malignancy.
Performing an image-guided percutaneous needle biopsy can
provide enough tissue for both culture and pathology in
many cases that will exclude many of these confounding diag-
noses [109]. In addition, the absence of any tissue abnormality
suggests that the biopsy performed did not sample the correct
area of abnormality. There is limited knowledge on the variables
that are associated with accuracy of the image-guided biopsy.
Prior use of antimicrobial therapy, tissue or aspiration biopsy
volume, the size of the needle used, and sampling errors are
among the factors that may affect culture accuracy following
an image-guided aspiration biopsy [110]. In a retrospective
review of 800 patients undergoing imaging-guided diagnostic
bone biopsy, the highest rate of positive cultures was associated
with obtaining >2 mL of ﬂuid. The size of the needle used
(range, 11–18 gauge) and antibiotic administration before biop-
sy did not have a signiﬁcant impact on the yield [110].
In patients with high clinical and radiologic suspicion and a
nondiagnostic ﬁrst image-guided aspiration biopsy, a second
or an open biopsy to establish a pathologic and microbiologic
diagnosis should be considered. The presence of granuloma-
tous inﬂammatory changes will prompt the evaluation for tu-
berculosis. In tuberculous NVO, histological ﬁndings may
include the presence of caseating necrosis and giant cell for-
mation with or without a positive Ziehl-Neelsen stain for
acid-fast bacilli. In the prepurulent phase of granulation tissue,
the inﬂammatory reaction spreading throughout the vessels of
the vertebral body can be seen, resulting in bony necrosis. In
addition, there may be a pathological fracture with sequestrum
formation, compromising the spinal canal. The disc space is
usually not involved, but the disc itself lies in a pool of exu-
dates. Paraspinal abscess formation is the hallmark of active
tuberculosis. The abscess cavity, surrounded by a wall of
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granulation tissue, may be in contact with the dura. In contrast,
brucellar NVO is characterized by noncaseating granulomas with
negative acid-fast staining and the presence of gram-negative coc-
cobacilli on Gram stain.
Nontuberculous mycobacteria; and fungal infections, includ-
ing aspergillosis, blastomycosis, and coccidiomycosis, may also
cause granulomatous changes without caseation.
VII. What Is the Preferred Next Step in Patients With
Nondiagnostic Image-Guided Aspiration Biopsy and Suspected
NVO?
Recommendations
21. In the absence of concomitant bloodstream infection, we
recommend obtaining a second aspiration biopsy in patients
with suspected NVO in whom the original image-guided as-
piration biopsy grew a skin contaminant (coagulase-negative
staphylococci [except S. lugdunensis], Propionibacterium
species, or diphtheroids) (strong, low).
22. In patients with nondiagnostic ﬁrst image-guided aspira-
tion biopsy, and suspected NVO, further testing should be
done to exclude difﬁcult-to-grow organisms (eg, anaerobes,
fungi, Brucella species, or mycobacteria) (strong, low).
23. In patients with suspected NVO and a nondiagnostic image-
guided aspiration biopsy and laboratory workup, we suggest
either repeating an image-guided aspiration biopsy, perform-
ing percutaneous endoscopic discectomy and drainage, or
proceeding with an open excisional biopsy (weak, low).
Evidence Summary
Identifying the offending pathogen is crucial for appropriate an-
timicrobial therapy. Performing an image-guided percutaneous
needle aspiration biopsy is a relatively safe and inexpensive di-
agnostic tool [73, 111, 112]. The relevance of a positive culture
obtained by this technique is generally to conﬁrm the clinical
and/or radiologic suspicion of NVO and to identify the patho-
gen responsible for the infection. When isolating a common
skin contaminant such as Staphylococcus epidermidis, Propioni-
bacterium acnes, or diphtheroids, efforts should be made to
exclude contamination and to try to eliminate the possibility
of other pathogens such as tuberculosis, Brucella, or fungal
pathogens. Further serology and molecular testing might be
of help.
In cases where the ﬁrst image-guided aspiration biopsy is
nondiagnostic, appropriate additional testing to exclude brucel-
lar, fungal, or mycobacterial cultures may be obtained [30, 52].
A repeat image-guided aspiration biopsy or a percutaneous
PEDD surgical biopsy will improve the sensitivity of the culture
results. The decision to perform an image-guided biopsy or a
PEDD depends on the yield of an image-guided biopsy in a
particular center and its availability [1, 30, 54, 113]. PEDD is an
easy technique that presents a sufﬁcient amount of tissue for
microbiologic examination obtained directly from the infected
disc region, providing higher diagnostic accuracy. Yang et al iden-
tiﬁed causative bacteria more frequently with PEDD than with
image-guided biopsy (18 of 20 [90%] vs 15 of 32 [47%] patients)
[114]. Whereas image-guided biopsy has variable rates (36%–
91%) for bacteriologic diagnosis in patients with spinal infections
[5, 84, 115–118], PEDD is a new simple technique that is proving
to have a better diagnostic accuracy [114, 119–121]. If vertebral
osteomyelitis is still highly suspected after a nondiagnostic second
image-guided aspiration biopsy or PEDD, an open biopsy may be
warranted.
When surgical intervention is indicated for decompression
because of an epidural abscess or other neurologic complica-
tions, excisional biopsy should be done without the need for a
preceding image-guided aspiration biopsy.
RECOMMENDATIONS FOR CLINICAL THERAPY
VIII. When Should Empiric Antimicrobial Therapy Be Started in
Patients With NVO?
Recommendations
24. In patients with normal and stable neurologic examination
and stable hemodynamics, we suggest holding empiric anti-
microbial therapy until a microbiologic diagnosis is estab-
lished (weak, low).
25. In patients with hemodynamic instability, sepsis, septic
shock, or progressive or severe neurologic symptoms, we sug-
gest the initiation of empiric antimicrobial therapy in con-
junction with an attempt at establishing a microbiologic
diagnosis (weak, low).
Evidence Summary
In a single-center retrospective cohort study, the use of pre-
biopsy empiric antibiotics did not affect the sensitivity of cul-
ture results [87]. Given the limitations in study methodology,
however, the panel believes that in patients with suspected
NVO, prior use of empiric antimicrobial therapy may affect
the sensitivity of establishing a microbiologic diagnosis. Most
evaluated patients with suspected NVO are hemodynamically
stable and have no neurologic symptoms. Attempt at establish-
ing the diagnosis prior to the use of empiric antimicrobial ther-
apy would improve the sensitivity of culture results obtained via
either a percutaneous image-guided biopsy or an open biopsy.
In clinical circumstances where empiric antimicrobial therapy is
deemed appropriate, physicians should use regimens that would
include coverage against staphylococci, including methicillin-
resistant S. aureus (MRSA), streptococci, and gram-negative
bacilli. Such regimens might include a combination of vancomy-
cin and a third- or fourth-generation cephalosporin. Alternative
regimens, in case of allergy or intolerance, might include a com-
bination of daptomycin and a quinolone. The use of empiric
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antifungal and antimycobacterial therapy is not appropriate in
most situations. Empiric antimicrobial therapy is dependent on
the host, the clinical situation, and the epidemiologic risk, as
well as the local historical in vitro susceptibility data. Several em-
piric antimicrobial regimens were suggested by the panel mem-
bers. This might include regimens that have coverage against
staphylococci, including oxacillin-resistant strains, as well as the
coverage of aerobic gram-negative bacilli (Table 2). Selected reg-
imens that were discussed might include vancomycin in combi-
nation with ciproﬂoxacin, vancomycin in combination with
cefepime, or vancomycin in combination with a carbapenem.
The panel was not in favor of routine use of empiric regimens
that include coverage against anaerobes or fungal, brucellar, or
mycobacterial organisms.
Table 2. Parenteral Antimicrobial Treatment of Common Microorganisms Causing Native Vertebral Osteomyelitis
Microorganism First Choicea Alternativesa Commentsb
Staphylococci, oxacillin
susceptible
Nafcillinc sodium or oxacillin 1.5–2
g IV q4–6 h or continuous
infusion
or
Cefazolin 1–2 g IV q8 h
or
Ceftriaxone 2 g IV q24 h
Vancomycin IV 15–20 mg/kg q12 hd
or daptomycin 6–8 mg/kg IV q24 h
or linezolid 600 mg PO/IV q12 h or
levofloxacin 500–750 mg PO q24
h and rifampin PO 600 mg daily
[122] or clindamycin IV 600–900
mg q8 h
6 wk duration
Staphylococci, oxacillin
resistant [123]
Vancomycin IV 15–20 mg/kg q12 h
(consider loading dose, monitor
serum levels)
Daptomycin 6–8 mg/kg IV q24 h or
linezolid 600 mg PO/IV q12 h or
levofloxacin PO 500–750 mg PO
q24 h and rifampin PO 600 mg
daily [122]
6 wk duration
Enterococcus species,
penicillin susceptible
Penicillin G 20–24 million units IV
q24 h continuously or in 6
divided doses; or ampicillin
sodium 12 g IV q24 h
continuously or in 6 divided
doses
Vancomycin 15–20 mg/kg IV q12 h
(consider loading dose, monitor
serum levels) or daptomycin 6
mg/kg IV q24 h or linezolid 600
mg PO or IV q12 h
Recommend the addition of 4–6 wk of
aminoglycoside therapy in patients
with infective endocarditis. In patients
with BSI, physicians may opt for a
shorter duration of therapy. Optional
for other patients [124, 125].
Vancomycin should be used only in case
of penicillin allergy.
Enterococcus species,
penicillin resistante
Vancomycin IV 15–20 mg/kg q12 h
(consider loading dose, monitor
serum levels)
Daptomycin 6 mg/kg IV q24 h or
linezolid 600 mg PO or IV q12 h
Recommend the addition of 4–6 wk of
aminoglycoside therapy in patients
with infective endocarditis. In patients
with BSI, physicians may opt for a
shorter duration of aminoglycoside.
The additional of aminoglycoside is
optional for other patients [124, 125].
Pseudomonas
aeruginosa
Cefepime 2 g IV q8–12 h or
meropenem 1 g IV q8 h or
doripenem 500 mg IV q8 h
Ciprofloxacin 750 mg PO q12 h (or
400 mg IV q8 h) or aztreonam 2 g
IV q8 h for severe penicillin allergy
and quinolone-resistant strains or
ceftazidime 2 g IV q8 h
6 wk duration
Double coverage may be considered
(ie, β-lactam and ciprofloxacin or
β-lactam and an aminoglycoside).
Enterobacteriaceae Cefepime 2 g IV q12 h
or ertapenem 1 g IV q24 h
Ciprofloxacin 500–750 mg PO q12 h
or 400 mg IV q12 hours
6 wk duration
β-hemolytic
streptococci
Penicillin G 20–24 million units IV
q24 h continuously or in 6
divided doses or ceftriaxone 2 g
IV q24 h
Vancomycin IV 15–20 mg/kg q12 h
(consider loading dose, monitor
serum levels)
6 wk duration
Vancomycin only in case of allergy.
Propionibacterium
acnes
Penicillin G 20 million units IV q24 h
continuously or in 6 divided
doses or ceftriaxone 2 g IV q24 h
Clindamycin 600–900 mg IV q8 h
or vancomycin IV 15–20 mg/kg
q12 h (consider loading dose,
monitor serum levels)
6 wk duration
Vancomycin only in case of allergy.
Salmonella species Ciprofloxacin PO 500 mg q12 h or
IV 400 mg q12 h
Ceftriaxone 2 g IV q24 h (if nalidixic
acid resistant)
6–8 wk duration
Abbreviations: BSI, bloodstream infection; IV, intravenous; PO, take orally; q, every.
a Antimicrobial dosage needs to be adjusted based on patients’ renal and hepatic function. Antimicrobials should be chosen based on in vitro susceptibility as well as
patient allergies, intolerances, and potential drug interactions or contraindications to a specific antimicrobial.
b Recommend Infectious Diseases Society of America guidelines for monitoring of antimicrobial toxicity and levels [126].
c Flucloxacillin may be used in Europe.
d Vancomycin should be restricted to patients with type I or documented delayed allergy to β-lactams.
e Daptomycin, linezolid, or Synercid may be used for vancomycin-resistant enterococci.
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IX. What Is the Optimal Duration of Antimicrobial Therapy in
Patients With NVO?
Recommendations
26. We recommend a total duration of 6 weeks of parenteral or
highly bioavailable oral antimicrobial therapy for most
patients with bacterial NVO (strong, low).
27. We recommend a total duration of 3 months of antimicro-
bial therapy for most patients with NVO due to Brucella
species (strong, moderate).
Evidence Summary
There is a single published randomized clinical trial that showed
that 6 weeks of antibiotic treatment is noninferior to 12 weeks in
patients with NVO [127]. In this open-label, multicenter, non-
inferiority randomized trial, 160 of 176 (90.9%) patients in the
6-week group and 159 of 175 (90.9%) of those in the 12-week
group were clinically cured. The duration of initial course of an-
timicrobial therapy has ranged from 4 to 12 weeks in most pub-
lished cohorts describing the experience of single centers [6, 7,
128]. In an observational study of 91 patients with NVO by Ro-
blot et al comparing the outcomes in patients treated with ≤6
weeks vs ≥6 weeks, the rates of relapse and death were similar
in both groups [129]. In this retrospective review, the 2 study
groups appeared to have similar characteristics. In a recently
published retrospective cohort study of 61 patients with NVO,
a switch to an oral antimicrobial therapy was performed in 72%
of patients after a median intravenous therapy of 2.7 weeks. In
this small cohort, no recurrence was observed. The authors con-
cluded that early switch to an oral regimen may be safe, provid-
ed that CRP has decreased and epidural or paravertebral
abscesses of signiﬁcant size have been drained [130]. Prolonged
antibiotic treatment has been recommended in most patients
with NVO. The rationale behind the prolonged duration mostly
stems from the limited bone penetration of most antimicrobials
used in patients with NVO, the need for several weeks for bone
to revascularize following surgery, and the limited experience
derived from trials in pediatric patients with hematogenous
long bone osteomyelitis [131–134]. The failure rates of treated
patients with NVO in most clinical studies has varied between
10% and 30%. Factors associated with worse outcome have not
been well deﬁned but might include multidisc disease, the pres-
ence of concomitant epidural abscess, lack of surgical therapy,
infection with S. aureus, old age, or the presence of signiﬁcant
comorbidities. In an observational nonrandomized study,
Daver et al compared the failure rate of patients with staphylo-
coccal osteomyelitis including some with vertebral osteomyelitis
treated with an early switch to oral antibiotics (median duration
of intravenous treatment was 12 days, followed by 42 days of
oral therapy) vs a prolonged parenteral course (median treat-
ment duration, 42 days intravenous followed by 21 days oral).
The success rate was 69% in the prolonged intravenous group
vs 78% in the early switch group [135]. Selected panel members
advocate the use of longer treatment duration for >6 weeks fol-
lowed by a course of oral therapy for 3 months or longer in pa-
tients perceived to be at high risk for failure (ie, MRSA,
extensive infection). The use of this strategy should be weighed
against the lack of data to support its efﬁcacy and the potential
for adverse reactions associated with prolonged use of antimi-
crobial therapy, including emergence of resistant pathogens
and Clostridium difﬁcile colitis [6, 128, 133, 136, 137]. Parenteral
antimicrobial therapy is the standard mode of treatment for the
majority of gram-positive and selected gram-negative microor-
ganisms (Table 2). However, oral antimicrobials with excellent
bioavailability, including ﬂuoroquinolones, linezolid, and met-
ronidazole, allow the possibility of an early switch to the oral
route without compromising efﬁcacy. This especially applies
to the use of quinolones for patients with aerobic gram-negative
bacilli. Oral β-lactams should not be prescribed for the initial
treatment of NVO given their low bioavailability (Table 3).
The management of brucellar NVO was the subject of a re-
view of 96 patients from a single tertiary referral center from
Spain. From this cohort, 65.6% of patients were treated with an-
timicrobial therapy alone. The 2 most commonly used regimens
included a combination of streptomycin for 2–3 weeks and dox-
ycycline for 3 months, or doxycycline and rifampin (both for 3
months). Twenty percent of patients treated in this cohort expe-
rienced treatment failure, with no signiﬁcant difference between
patients treated with doxycycline-streptomycin and those treat-
ed with doxycycline-rifampin [93].
The management of patients with mycobacterial vertebral os-
teomyelitis are outlined in other IDSA-sponsored guidelines
[138]. The management of patients with fungal NVO is ad-
dressed in the referenced IDSA guidelines [62–66].
X. What Are the Indications for Surgical Intervention in Patients
With NVO?
Recommendations
28. We recommend surgical intervention in patients with pro-
gressive neurologic deﬁcits, progressive deformity, and spinal
instability with or without pain despite adequate antimicro-
bial therapy (strong, low).
29. We suggest surgical debridement with or without stabiliza-
tion in patients with persistent or recurrent bloodstream in-
fection (without alternative source) or worsening pain
despite appropriate medical therapy (weak, low).
30. We advise against surgical debridement and/or stabiliza-
tion in patients who have worsening bony imaging ﬁndings
at 4–6 weeks in the setting of improvement in clinical symp-
toms, physical examination, and inﬂammatory markers
(weak, low).
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Evidence Summary
The goals of surgical debridement are to debulk infected tissue,
to secure an adequate blood supply for tissue healing, and to
maintain or restore spinal stability. The indications for surgery
have been solely derived from cohorts that identiﬁed conditions
that are associated with a high risk for recurrence. The indica-
tions for surgery may include the presence of neurologic com-
promise, signiﬁcant vertebral destruction with instability, large
epidural abscess formation, intractable back pain, or failure of
medical treatment.
A number of surgical management strategies have been dis-
cussed in the literature. None of these approaches have been
subjected to randomized clinical trials. These options include
an anterior or posterior approach, single vs staged surgery,
with or without instrumentation [139].
In a cohort of disc space infection by McHenry et al that in-
cluded some patients with spinal implant–associated infections,
109 of 253 patients underwent surgical management. The most
frequent indications for surgery in this cohort were drainage of
abscesses (85 patients); relief of compression of the spinal cord,
cauda equina, or nerve roots (48 patients); and spinal stabiliza-
tion (32 patients). The outcome was favorable in 86 of 109 pa-
tients (79%). Of the 48 patients with neurologic impairment
who underwent surgical treatment via an anterior or posterior
approach, the outcome was favorable for 33 (69%) [6].
Valancius et al reviewed the management strategies in 196
patients with NVO seen in a single institution over a 10-year
period, of whom 100 patients required surgical intervention
[140]. Forty-six (39.3%) patients had neurologic compromise,
3 (2.5%) of them presented with cauda equina syndrome, and
10 (8.5%) were paraplegic. Four different surgical strategies
were used, including posterior debridement with pedicle
screw instrumentation (75 patients), and 19 patients were de-
brided without instrumentation. Seven patients underwent an-
terior debridement alone. In 16 cases, a combined anterior
debridement with posterior pedicle screw instrumentation was
performed. Twenty-four patients required repeat surgery; 12
(10%) had mild neurological impairment, and 4 were paraple-
gic. Twenty-seven patients (23%) had chronic residual pain of
varying degrees [140].
RECOMMENDATIONS FOR CLINICAL
FOLLOW-UP
XI. How Should Failure of Therapy Be Deﬁned in Treated Patients
With NVO?
Recommendation
31. We suggest that persistent pain, residual neurologic deﬁ-
cits, elevated markers of systemic inﬂammation, or radio-
graphic ﬁndings alone do not necessarily signify treatment
failure in treated NVO patients (weak, low).
Evidence Summary
Patient outcomes of bacterial NVO have improved dramatically
since the preantibiotic era, when the diagnosis carried a mortal-
ity rate of approximately 25% [141]. In contemporary cohorts,
mortality rates have ranged between 0% and 11% [6, 7, 113, 142,
143]. Frequently, clinicians are faced with NVO patients who
exhibit some degree of clinical, laboratory, or radiographic evi-
dence suggesting possible persistent or recurrent infection.
There is no consensus in the literature for how one should
Table 3. Selected Oral Antibacterial Agents With Excellent Oral
Bioavailability Commonly Used to Treat Patients With Native
Vertebral Osteomyelitis
Oral Agents Comments
Metronidazole 500 mg PO
tid to qid
Can be used in the intital course of NVO
due to Bacteroides species and other
susceptible anaerobes.
Moxifloxacin 400 mg PO
once daily
Is not recommended for use in patients
with staphylococcal NVO, but may be
used in patients with NVO due to
Enterobacteriaceae and other
susceptible aerobic gram-negative
organisms.
Linezolid 600 mg PO bid Can be used in the intital course of NVO
due to oxacillin-resistant staphylocci
when first-line agents cannot be used.
Levofloxacin 500–750 mg
PO once daily
Is not recommended for use in patients
with staphylococcal NVO as
monotherapy but may be used in
patients with NVO due to
Enterobacteriaceae and other
susceptible aerobic gram-negative
organisms.
Ciprofloxacin 500–750 mg
PO bid
Is not recommended for use in patients
with staphylococcal NVO but may be
used in patients with NVO due to
Enterobacteriaceae and other
susceptible aerobic gram-negative
organisms including Pseudomonas
aeruginosa and Salmonella species.
TMX-SMX 1–2 double
strength tabs PO bid
Is not recommended for use in patients
with staphylococcal NVO but may be
recommended as a second-line agent
in patients with NVO due to
Enterobacteriaceae and other
susceptible aerobic gram-negative
organisms. May need to monitor
sulfamethoxazole levels.
Clindamycin 300–450 mg
PO qid
Recommended as second-line choice
for sensitive staphylococcal NVO.
Doxycycline and rifampin Mostly used in patients with brucellar
NVO.
Dosages need to be adjusted based on patients’ renal and hepatic function.
Antimicrobials should be chosen based on in vitro susceptibility as well as
patient allergies, intolerances, and potential drug interactions or contraindications
to a specific antimicrobial.
Abbreviations: bid, twice daily; NVO, native vertebral osteomyelitis; PO, take
orally; qid, 4 times daily; tid, 3 times daily; TMP-SMX, trimethoprim-
sulfamethoxazole.
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deﬁne treatment failure in NVO patients. The most speciﬁc
measure of treatment failure is microbiologically conﬁrmed
persistent infection despite receipt of targeted antimicrobial
therapy for an appropriate duration [5, 13]. Microbiologically
conﬁrmed treatment failure rates occur in 0%–11% of NVO pa-
tients in contemporary cohorts [6, 7, 15, 113, 129, 142, 143]. We
propose that the deﬁnition of treatment failure above be used to
standardize future outcome reporting in NVO patients.
Historically, treatment failure was often based upon surrogate
markers, such as systemic inﬂammatory markers, radiographic
results, and the clinical status of the patient without an empha-
sis on microbiologic conﬁrmation. Ascribing treatment failure
to NVO patients in the absence of microbiologic evidence
may lead to overestimation of treatment failure [14, 15] and pre-
dispose patients to potentially unnecessary medical and surgical
interventions [14, 15, 144]. Adverse outcomes, such as long-
term functional status, neurologic status, and residual pain
have been frequently reported as secondary outcomes when as-
sessing the effectiveness of therapy [6, 145–147].However, these
measures may better reﬂect the extent of infection at the time of
diagnosis, the premorbid functional status of the patient, or pa-
tient comorbidities rather than the effectiveness of antimicrobi-
al treatment in eradicating infection.
XII. What Is the Role of Systemic Inﬂammatory Markers and MRI
in the Follow-up of Treated Patients With NVO?
Recommendations
32. We suggest monitoring systemic inﬂammatory markers
(ESR and or CRP) in patients with NVO after approximately
4 weeks of antimicrobial therapy, in conjunction with a clin-
ical assessment (weak, low).
33. We recommend against routinely ordering follow-up MRI
in patients with NVO in whom a favorable clinical and lab-
oratory response to antimicrobial therapy was observed
(strong, low).
34. We suggest performing a follow-up MRI to assess evolu-
tionary changes of the epidural and paraspinal soft tissues
in patients with NVO who are judged to have a poor clinical
response to therapy (weak, low).
Evidence Summary
Monitoring patients’ clinical response to treatment and follow-
up values for systemic inﬂammatory markers may help identify
patients at greater risk for treatment failure [148–151]. Paradox-
ically, values may increase within the ﬁrst few weeks of diagno-
sis and treatment despite clinical improvement otherwise [14].
Patients with at least a 25%–33% reduction in systemic inﬂam-
matory markers after receipt of approximately 4 weeks of anti-
microbial therapy may be at reduced risk of treatment failure
[14, 148]. NVO patients with a 50% reduction in ESR after 4
weeks rarely develop treatment failure. In one study, it was
found that after 4 weeks of treatment, ESR values >50 mm/
hour and CRP values >2.75 mg/dL may confer a signiﬁcantly
higher risk of treatment failure [151]. CRP has been shown to
improve more rapidly in patients with spine infection and
may correlate more closely with the clinical status of the patient
[150]. However, most patients in whom systemic inﬂammatory
markers do not drop signiﬁcantly or continue to be high during
4- to 8-week follow-up have successful outcomes, highlighting
the poor speciﬁcity of these markers [14]. Therefore, values
should be interpreted in concert with the clinical status of the
patient. Patients deemed to have a poor clinical response to
therapy (eg, persistent or progressive pain, systemic symptoms
of infection) and elevated systemic inﬂammatory markers may
be at highest risk for treatment failure [14, 151].
NVO patients who demonstrate favorable clinical and labora-
tory response to therapy do not need to undergo follow-up MRI
[144, 148, 149, 152–154]. Follow-up imaging performed <4
weeks after the baseline exammay falsely suggest progressive in-
fection despite clinical improvement, particularly when consid-
ering vertebral body and disc space ﬁndings. This radiographic
phenomenon may inﬂuence clinicians to perform unnecessary
surgical debridement or prolongation of antibiotic therapy. Ad-
ditionally, radiographic evidence of ongoing inﬂammation may
persist for months to years in patients without clinically relevant
implications [144, 148, 149, 152–154].
Appropriately timed and interpreted follow-up MRI may
provide prognostic information regarding treatment failure in
NVO patients with an unfavorable response to therapy [16,
148]. Improvement in paravertebral and epidural soft tissue
on follow-up MRI correlates best with improvement in clinical
status and outcomes. Compared to baseline MRI, follow-up
exams often demonstrate similar or worsened inﬂammatory
characteristics of the bone and disc structures, despite clinically
improved patients and ultimately successful treatment. MRI
ﬁndings of the soft tissues, such as paravertebral and epidural
inﬂammatory changes and abscesses, may correlate better
with clinical status and treatment outcomes. In patients with
worsened soft tissue ﬁndings on MRI 4–8 weeks after diagnosis,
microbiologically conﬁrmed treatment failure rates as high as
44% are reported [144, 148, 149, 152–154].
XIII. How Do You Approach a Patient With NVO and Suspected
Treatment Failure?
Recommendations
35. In patients with NVO and suspected treatment failure, we
suggest obtaining markers of systemic inﬂammation (ESR
and CRP). Unchanged or increasing values after 4 weeks of
treatment should increase suspicion for treatment failure
(weak, low).
36. We recommend obtaining a follow-up MRI with emphasis
on evolutionary changes in the paraspinal and epidural soft
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tissue ﬁndings in patients with NVO and suspected treat-
ment failure (strong, low).
37. In patients with NVO and clinical and radiographic evidence
of treatment failure, we suggest obtaining additional tissue sam-
ples for microbiologic (bacteria, fungal, and mycobacterial) and
histopathologic examination, either by image-guided aspiration
biopsy or through surgical sampling (weak, very low).
38. In patients with NVO and clinical and radiographic evi-
dence of treatment failure, we suggest consultation with a
spine surgeon and an infectious disease physician (weak,
very low).
Evidence Summary
The most consistent ﬁnding in NVO treatment failure is persis-
tent or recurrent severe back pain [6]. However, many patients
with NVO otherwise thought to be cured report persistent pain
at the time of last follow-up [6, 146, 147]. Patients with persistent
or progressive pain, systemic symptoms of infection, undrained
or partially drained large epidural abscess, or persistently elevated
systemic inﬂammatory markers may be at highest risk for treat-
ment failure. Additional clinical ﬁndings associated with treat-
ment failure include diabetes mellitus, intravenous drug use,
recurrent bloodstream infection, new-onset neurologic deﬁcits,
and sinus tract formation [6, 129, 142].Rarely, patients may dem-
onstrate persistent evidence of systemic infection despite antibi-
otic therapy, which may suggest failure of medical therapy and
the need for surgical intervention [7].
There are limited data to guide the diagnostic approach to
NVO patients with suspected treatment failure. Obtaining sys-
temic inﬂammatory markers and a follow-up MRI may conﬁrm
the risk of treatment failure, clarify the presence of abscess in
need of drainage, and identify spinal instability that could beneﬁt
from surgical correction. Patients with evidence of progressive
epidural and/or paraspinal soft tissue infection on follow-up
MRI appear to be at a greater risk for treatment failure [148].
The frequency and utility of obtaining follow-up inﬂammatory
laboratory markers (ESR, CRP) while patients are receiving anti-
microbial therapy for NVO have not been established.
Therapeutic management of NVO patients with treatment
failure should be tailored to the suspected reason for failure.
Consultation with a surgeon and infectious disease physician
experienced in the treatment of spinal infections may be war-
ranted in patients with suspected or proven treatment failure.
NVO patients with established treatment failure have been
treated successfully with medical therapy alone or combined
medical/surgical therapy. The decision of whether surgical in-
tervention is warranted needs to be individualized, and incorpo-
rates similar principles as to whether to perform surgery at the
time of NVO diagnosis or not.
In NVO patients with suspected treatment failure in whom
surgical debridement is not planned, one should consider
image-guided aspiration biopsy to deﬁnitively establish the di-
agnosis of treatment failure and conﬁrm microbiologic etiology.
For culture-negative NVO patients with suspected treatment
failure, we recommend undertaking additional attempts to iso-
late an etiologic pathogen. This should include obtaining tissue
for histopathology; aerobic and anaerobic bacterial cultures; and
fungal, brucellar, and mycobacterial cultures. In select circum-
stances, serologic assays for uncommon causes of NVO should
be considered as well.
RESEARCH GAPS
One of the steps in developing a rational clinical research agen-
da in NVO is the identiﬁcation of evidence-based gaps in infor-
mation. The process of guideline development outlined above
serves as a natural means by which such gaps are identiﬁed.
Clinical questions identiﬁed by the NVO guideline authors
could shape a research agenda for the diagnosis and manage-
ment of NVO. Questions are included below.
Diagnostics
1. What are the risk factors associated with the development
of NVO?
2. How to develop and validate diagnostic algorithms in pa-
tients with suspected NVO?
3. What is the best strategy for patients with a nondiagnostic
ﬁrst aspiration biopsy?
4. What is the optimal timing for withholding antimic-
robial therapy prior to image-guided diagnostic aspiration
biopsy?
5. What is the optimal size of the needle to be used in image-
guided aspiration biopsy and the number of specimens to be
submitted in patients with suspected NVO?
6. What is the optimal timing and role of PEDD in patients
with suspected NVO?
7. What is the role of [18F]-ﬂuorodeoxyglucose PET scan-
ning in diagnosis of patients with NVO?
8. Is there a role for of novel inﬂammatory cytokines in the
diagnosis of NVO and follow-up of patients with NVO (ie, pro-
calcitonin, IL-6)?
9. What is the optimal role for the use of molecular diagnos-
tic techniques in the diagnosis of NVO?
Management
1. What are the optimal and most cost-effective algorithms
of surgical and medical treatment strategies for the manage-
ment of patients with NVO?
2. What is the optimal duration of parenteral therapy?
3. What are the role, timing, and duration of oral antimicro-
bial therapy as an alternative or following a course of parenteral
therapy?
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Follow-up
1. Which factors, including demographics, microbiology,
serum inﬂammatory markers, and imaging studies are useful
in predicting the outcome of patients with NVO?
2. How should we manage patients with persistent elevation
of inﬂammatory markers after a course of parenteral antimicro-
bial therapy?
3. What is the utility of obtaining weekly follow-up inﬂam-
matory laboratory markers (ESR, CRP) while patients are re-
ceiving antimicrobial therapy for NVO?
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